Disease-modifying agents such as β-interferons and glatiramer acetate have a significant impact on slowing the course of relapsing-remitting multiple sclerosis (MS). Therapeutic guidelines recommend initiating therapy with 1 of the 3 agents shortly after diagnosis of clinically definite MS, but there is insufficient data to specifically select one of the therapies. New research helps differentiate the therapies based on their induction of neutralizing antibodies, optimal dosing, and monitoring strategies. New treatments for secondary progressive MS are also emerging with evidence for the use of interferon β-1b and the approval of mitoxantrone. Future therapies for MS include oral glatiramer acetate and combination therapy.
Levodopa continues to be the standard of care for the treatment of Parkinson’s disease, but the approval of newer therapies that spare the use of levodopa and improve safety profiles are changing the management of the disease. Dopamine agonists such as bromocriptine and pergolide have been used to manage complications of levodopa therapy in patients with advanced disease, but new research supports the use of the more selective dopamine agonists, pramipexole and ropinirole, as monotherapy in early Parkinson’s disease. The combination of a catechol-O-methyltransferase (COMT) inhibitor with levodopa provides a new therapeutic option for treating patients with motor complications in advanced disease.
Chappell JC, Cohen H.Frontiers in Pharmacotherapy, Part I: Alzheimer’s disease and Epilepsy. J Pharm Pract. 2002;15(3): 195-220.
2.
Noseworthy JH, Gold R, Hartung HP. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opinion Neurol. 1999;12(3):279-293.
3.
Rudick RA. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Arch Neurol. 1999;56:1079-1084.
4.
Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon β-1a in multiple sclerosis. Neurology. 1998;50(5):1266-1272.
5.
Kivisakk P, Alm GV, Fredrikson S, et al. Neutralizing and binding anti-interferon-beta (IFN-β) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol. 2000;7(1):27-34.
6.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
7.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285-294.
8.
Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871-882.
9.
Miller DM, Rudick RA, Cutter GRet al. Clinical significance of the Multiple Sclerosis Functional Composite: relationship to patient-reported quality of life. Arch Neurol. 2000;57:1319-1324.
10.
Cohen JA, Cutter GR, Fischer JS, et al. Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001;58:961-967.
11.
Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple Sclerosis. N Engl J Med. 2000;343(13):938-952.
12.
Zhao GJ, Koopmans RA, Li DK, et al. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. Neurology. 2000;54(1):200-206.
13.
Paty DW. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):662-667.
14.
Paolillo A, Bastianello S, Frontoni M, et al. Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. J Neurology. 1999;246(6):443-448.
15.
The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study. Neurology. 1999;53(4):679-686.
16.
Rice GP, Ebers GC, Lublin FD, et al. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology. 1999;52(9):1893-1895.
17.
Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon-beta 1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurology. 1999;46(6):850-859.
18.
Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
19.
Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 1998;50(3):701-708.
20.
Johnson KP. Author’s reply to: extended use of glatiramer acetate (Copaxone) for MS. Neurology. 1999; 52(4):897-898.
21.
Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment. Neurology. 2000;54(4):813-817.
22.
Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol. 2001;8:141-148.
23.
De Seze J, Edan G, Labalette M, et al. Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial. Ann Neurol. 2000;47(5):686.
24.
Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (Copolymer-1) and a type I interferon (IFN- alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol. 2000;47(1):127-131.
25.
Schwid SR, Trotter JL. Lessons from linomide: a failed trial, but not a failure. Neurology. 2000;54(9):1716-1717.
26.
Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. Neurology. 2000;54(9):1726-1733.
27.
Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. Neurology. 2000;54(9):1734-1741.
28.
Hartung HP, Gonsette R.The MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase-III trial: clinical results and 3-year follow-up. Neurology. 1999;52:A290.
29.
Cursiefen S, Flachenecker P, Toyka KV, et al. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis. Eur Neurol. 2000;43(3):186-187.
30.
Mitoxantrone (Novantrone®) [package insert]. Seattle, Wash: Immunex Corporation; March 2000.
31.
Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov Disord. 1999;14(6):911-913.
32.
Factor SA. Dopamine agonists. Med Clin North Am. 1999;83(2): 415-443.
Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson’s disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy. 1999;19(12):1437-1438.
37.
Taylor AC, Beerahee A, Citerone DR, et al. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson’s disease. Pharmacottherapy. 1999;19(2):150-156.
38.
Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Neurology. 1998:51(4):1057-1062.
39.
Lieberman A, Ranhosky A, Korts D.Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997:49:162-168.
40.
Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56 (suppl 5):S1-S88.
41.
Watts R.The role of dopamine agonists in early Parkinson’s disease. Neurology. 1997;49(suppl 1):S34-S38.
42.
Montastruc JL, Rascol O, Senar JM. Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord. 1999;14(5):725:730.
43.
Sethi KD, O’Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson’s disease: a 12-month experience. Arch Neurol. 1998;55(9)1211-1216.
44.
Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. Neurology. 1999;53(2):364-370.
45.
Rascol O, Brooks DJ, Korczyn AD, et al. A 5-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole of levodopa. N Engl J Med. 2000;342:1484-1491.
46.
Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD study. Clin Neuropharmacol. 2000;23(1):34-44.
47.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA. 2000;284(15):1931-1938.
48.
Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa-controlled trial. Drugs. 1998;55(suppl 1):23-30.
49.
Tanner CM. Dopamine agonists in early therapy for Parkinson disease: promise and problems. JAMA. 2000;284(15):1971-1973.
50.
Kunig G, Pogarell O, Moller JC, et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson’s disease. Clin Neuropharmacol. 1999;22(5):301-305.
51.
Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson’s disease treated with levodopa. Drugs. 1998;55(suppl 1):17-22.
52.
Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow?Neurology. 1999;52(6):1227-1229.
53.
Nutt J.Catechol-O-methyltransferase inhibitors for the treatment of Parkinson’s disease. Lancet1998;351:1221-1222.
54.
Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter trial. Neurology. 1999;53(5):1012-1019.
55.
Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J Neurol Neurosurg Psych. 2000;68:589-594.
56.
Hauser RA, Molho E, Shale H, et al. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson’s disease. Mov Disord. 1998;13(4):643-647.
57.
The Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. The Tolcapone Study Group. Mov Disord. 1999;14(1):38-44.
58.
Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51(5):1309-1314.
59.
Adler Ch, Singer C, O’Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol. 1998; 55(8):1089-1095.
60.
Luer MS. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications. Pharmacotherapy. 1999;19(suppl 11, pt 2):169S-179S.
61.
Lambert D, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs & Aging. 2000; 16(1):55-65.
62.
Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet. 1998;352:958.
63.
Anonymous. Roche Tasmar more frequent liver monitoring urged in EU label revision. FDC Rep Pink Sheet. 1998;60(42):17.
